Get the lastest analysis
Know what's happening as soon as it does. Benefit from our analysts' decades of insight and market projection experience to make your next move.
Free
Posted in: CAR-T, CD19 Apr 22 | 2024Obe-Cel Starts EMA Assessment in r/r B-ALL; April CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Apr 17 | 2024Carvykti Sales Flatten while Preparing for Launch in 2L MM; JNJ’s Q1 2024 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, CAR-T Apr 12 | 2024Kelonia and Carisma Report Preclinical Data from their Novel Platforms; AACR 2024 Analysis 3Access Free BlastFree
Posted in: Allogeneic, CAR-T Apr 11 | 2024Poseida, Caribou, and Takeda Presented Data for Hematological Malignancies; AACR 2024 Analysis 2Access Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Apr 09 | 2024CRISPR Tx, AZ, and MiNK Tx Report Data in Solid Tumors; AACR 2024 Analysis 1Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Apr 08 | 2024Carvykti and Abecma Receive FDA Approval for Early Lines of MMAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Mar 22 | 2024You May Have Missed: New Breyanzi Ph3 Trial for R/R FL; Abecma Approved for 3L MM in the EUAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Mar 20 | 2024Thoughts on the FDA ODAC Recommending Carvykti and Abecma in Earlier Lines of MMAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Mar 18 | 2024Allogene to Initiate Ph2 ALPHA3 Trial in Mid-2024; Updates from ALLO-316's TRAVERSE Study Expected in 2024; ALLO-329's Ph1 Trial in Autoimmune Diseases Set to Start in 2025; Allogene Q4 2023 Earnings CallAccess Free BlastFree
Posted in: CAR-T Mar 18 | 2024No Cell Therapy-Related Updates in March’s CHMP AgendaAccess Free Blast